NBIX

Neurocrine Biosciences, Inc.

134.18 USD
0.00 (0.00%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Neurocrine Biosciences, Inc. stock is down -5.61% since 30 days ago. The next earnings date is May 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 32.14% of the previous 27 February’s closed higher than January. In the last 10 Unusual Options Trades, there were 4 CALLs, 6 PUTs. 0% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
29 Jan 16:26 21 Jun, 2024 120.00 CALL 10 247
30 Jan 20:10 16 Feb, 2024 135.00 PUT 168 621
05 Feb 14:53 21 Jun, 2024 120.00 CALL 10 236
06 Feb 16:00 16 Feb, 2024 135.00 CALL 200 369
07 Feb 18:29 16 Aug, 2024 125.00 PUT 115 1
07 Feb 18:30 16 Aug, 2024 125.00 PUT 88 1
07 Feb 18:32 16 Aug, 2024 125.00 PUT 100 1
07 Feb 20:43 21 Jun, 2024 125.00 PUT 100 28
08 Feb 14:46 21 Jun, 2024 125.00 PUT 100 129
16 Feb 19:54 19 Apr, 2024 140.00 CALL 134 2

About Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc. discovers, develops, markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. Lead asset is INGREZZA, a VMAT2 inhibitor for the treatment of tardive dyskinesia. Company's commercial products include ONGENTYS, a catechol-O-methyltransferase inhibitor used as an adjunct therapy to levodopa/DOPA decarboxylase inhibitors for patients with Parkinson's disease.

  • Citigroup
    Thu Feb 8, 11:24
    hold
    confirm
  • Mizuho
    Thu Feb 8, 10:28
    hold
    confirm
  • Wells Fargo
    Thu Feb 8, 08:41
    hold
    confirm